SMARCA1 and lymphoma: We also found SWI mutations in GNAI2 (p.R179), in skin melanoma and lymphomas, where it has oncogenic effects by upregulating ERK1/2 [50], and in GNA13 (p.R200; in bladder carcinoma), which is not yet fully understood.